OZEM news

Roundhill GLP-1 & Weight Loss · Pharmaceuticals · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
35.9% of OZEM
Quartz · 28 Oct 2026, 16:16 UTC
Best-selling drugs 2026: 7 of the top 10 by 2025 sales
32.0% of OZEM
www.theepochtimes.com · 28 Oct 2026, 00:00 UTC
Judge Declines to Block Eli Lilly Weight-Loss Drug Ads in Dispute With Novo Nordisk
25.7% of OZEM
Seeking Alpha · 27 Oct 2026, 22:08 UTC
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) | Seeking Alpha
25.7% of OZEM
Where to buy OZEM
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
24/7 Wall St. · 28 Oct 2026, 19:24 UTC
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
12.7% of OZEM
Quartz · 28 Oct 2026, 17:20 UTC
Lilly's retatrutide more than doubled Ozempic weight loss in trial
13.0% of OZEM
Where to buy OZEM
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 15:55 UTC
Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha
12.7% of OZEM
Benzinga · 28 Oct 2026, 13:25 UTC
Eli Lilly Says Retatrutide Delivers More Than Double Ozempic's Weight Loss in Late-Stage Diabetes Trial -
12.7% of OZEM
24/7 Wall St. · 28 Oct 2026, 12:14 UTC
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
12.7% of OZEM
Market Screener · 28 Oct 2026, 12:07 UTC
Eli Lilly And Company Announces Positive Topline Results From TRANSCEND-T2D-2 Phase 3 Trial Of Retatrutide In Adults With Type 2 Diabetes
12.7% of OZEM
Quartz · 27 Oct 2026, 11:29 UTC
Judge rejects Novo Nordisk bid to block Eli Lilly weight-loss ads
25.7% of OZEM
Benzinga · 27 Oct 2026, 10:51 UTC
Novo Nordisk Loses Court Bid Against Eli Lilly's Weight-Loss Drug Ads -- Judge Says Sales Impact Was Negli
25.7% of OZEM
Benzinga · 28 Oct 2026, 10:04 UTC
Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings - Eli Lilly (NYSE:LLY)
12.7% of OZEM
Yahoo! Finance · 28 Oct 2026, 07:29 UTC
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
12.7% of OZEM
Business Insider · 28 Oct 2026, 00:00 UTC
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
12.7% of OZEM
Yahoo! Finance · 27 Oct 2026, 23:28 UTC
$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Today
12.7% of OZEM
The Boston Globe · 27 Oct 2026, 22:09 UTC
MGH, Brigham, other hospitals sue Eli Lilly, alleging 'extortion' in drug discount program
12.7% of OZEM
Bloomberg Business · 26 Oct 2026, 20:53 UTC
Novo Nordisk Loses Court Ruling Over Eli Lilly Obesity Drug Ads
25.7% of OZEM
Investing.com · 27 Oct 2026, 20:47 UTC
Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit By Reuters
12.7% of OZEM
Market Screener · 27 Oct 2026, 20:37 UTC
Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit
12.7% of OZEM

OZEM news

Where to buy OZEM

Where to buy OZEM